Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS
This article was originally published in Scrip
Cytokinetics lost $303m worth of market value on 25 April after the company reported that its drug tirasemtiv caused a greater numerical loss of function for individuals with amyotrophic lateral sclerosis (ALS) than placebo in the 711-patient Phase IIb BENEFIT-ALS clinical trial.
You may also be interested in...
The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.
Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.